Zurich Cantonal Bank
MLYS icon

Zurich Cantonal Bank’s Mineralys Therapeutics MLYS Stock Holding History

Zurich Cantonal Bank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Sell
18,892
-749
-4% -$20.6K ﹤0.01% 1927
2026
Q1 		$532K Buy
19,641
+2,293
+13% +$67.2K ﹤0.01% 1801
2025
Q4 		$630K Sell
17,348
-4,970
-22% -$199K ﹤0.01% 1639
2025
Q3 		$846K Sell
22,318
-556
-2% -$12K ﹤0.01% 1385
2025
Q2 		$309K Buy
+22,874
New +$331K ﹤0.01% 1943

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Zurich Cantonal Bank's MLYS Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Mineralys Therapeutics (MLYS) stake by 3.8% in Q2 2026, selling an estimated $20.6K and leaving 18,892 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #1927.

Zurich Cantonal Bank first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $846K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Zurich Cantonal Bank held 18,892 shares of Mineralys Therapeutics worth $510K as of Q2 2026.
  • Zurich Cantonal Bank sold 749 Mineralys Therapeutics shares in Q2 2026, an estimated $20.6K.
  • Mineralys Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1927 holding.
  • Zurich Cantonal Bank first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Zurich Cantonal Bank's Mineralys Therapeutics position peaked at $846K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.